D81.3 Adenosine deaminase [ADA] deficiency

Name of the Condition

• Adenosine deaminase [ADA] deficiency

Summary

Adenosine deaminase (ADA) deficiency is a rare inherited disorder that impairs the immune system, leading to severe combined immunodeficiency (SCID). This condition results from genetic mutations that reduce or eliminate the activity of the ADA enzyme, disrupting the development and function of lymphocytes (T cells, B cells, and natural killer cells). The deficiency causes a buildup of toxic metabolites, which damage immune cells and impair the body's ability to fight infections. Without treatment, ADA deficiency is typically fatal in early childhood due to recurrent, severe infections.

Causes

ADA deficiency is caused by genetic mutations in the ADA gene, which provides instructions for producing the adenosine deaminase enzyme. These mutations disrupt the enzyme's function, leading to the accumulation of toxic substances that destroy lymphocytes. The condition is inherited in an autosomal recessive pattern, meaning an individual must inherit two mutated copies of the gene (one from each parent) to develop the disorder. Carriers (those with one mutated copy) typically do not show symptoms.

Risk Factors

• Genetic predisposition, often with a family history of immunodeficiency disorders.
• Consanguinity (parents who are closely related) increasing the risk of autosomal recessive forms.
• Certain ethnic backgrounds with higher prevalence of specific genetic mutations.

Symptoms

• Recurrent, severe, or persistent infections (e.g., bacterial, viral, fungal).
• Failure to thrive or delayed growth in infants and children.
• Chronic diarrhea or gastrointestinal issues.
• Skin rashes or other dermatological problems.
• Respiratory infections (e.g., pneumonia, bronchitis).
• Lymphopenia (low lymphocyte count) detected in blood tests.

Diagnosis

Diagnosis of ADA deficiency involves a combination of clinical evaluation, laboratory testing, and genetic analysis. Blood tests may show low lymphocyte counts or abnormal immune function. Enzyme activity assays can measure ADA levels in red blood cells or other tissues. Genetic testing confirms the presence of mutations in the ADA gene. Prenatal testing (e.g., chorionic villus sampling or amniocentesis) may be offered to families with a known history of the disorder.

Treatment Options

Treatment for ADA deficiency focuses on restoring immune function and may include:

• Enzyme replacement therapy: Regular injections of PEG-ADA (pegademase bovine) to supplement ADA enzyme activity.
• Hematopoietic stem cell transplantation (HSCT): The only curative option, involving the infusion of healthy stem cells to rebuild the immune system.
• Gene therapy: Experimental approaches to correct the genetic defect in the patient's own cells.
• Supportive care: Antibiotics, antivirals, or antifungals to manage infections, along with immunoglobulin replacement therapy.

Prognosis and Follow-Up

With early diagnosis and appropriate treatment (e.g., HSCT or enzyme replacement), prognosis improves significantly. Untreated, ADA deficiency is fatal in infancy due to infections. Long-term follow-up is essential to monitor immune function, manage complications, and adjust therapies. Regular blood tests and clinical assessments help track progress and detect issues early.

Complications

• Severe, life-threatening infections (e.g., sepsis, meningitis).
• Failure to thrive or developmental delays.
• Organ damage from chronic infections.
• Side effects from treatments (e.g., graft-versus-host disease in HSCT).
• Increased risk of certain cancers due to impaired immune surveillance.

Lifestyle & Prevention

• Avoid exposure to sick individuals or crowded places to reduce infection risk.
• Practice good hygiene (e.g., handwashing) to minimize pathogen exposure.
• Follow vaccination schedules tailored to immune status (live vaccines are typically avoided).
• Maintain a balanced diet and monitor growth in children.
• Genetic counseling for families with a history of ADA deficiency to assess recurrence risk.

When to Seek Professional Help

Seek immediate medical attention if:

• Recurrent or severe infections occur (e.g., persistent fever, difficulty breathing).
• Unexplained weight loss or failure to thrive is observed in infants/children.
• Skin rashes, diarrhea, or other symptoms worsen or persist.
• A family history of immunodeficiency suggests a potential genetic risk.

Tips for Medical Coders

When coding for ADA deficiency (ICD-10-CM code D81.3), ensure documentation supports the diagnosis, including clinical findings (e.g., recurrent infections, lymphopenia) and confirmatory tests (e.g., enzyme assays, genetic testing). Note that D81.3 is specific to ADA deficiency and should not be confused with other combined immunodeficiencies. Verify that the code aligns with the patient's documented condition and treatment history to ensure accurate reporting.